CRISPR, Recombinant DNA, and LAMP-Based Platforms for Monkeypox: Emerging Tools for Diagnosis and Therapeutic Development

CRISPR, Recombinant DNA, and LAMP-Based Platforms for Monkeypox: Emerging Tools for Diagnosis and Therapeutic Development

Author: Yukti Sabikhi, Anshika Singh, Sameen Masroor Sameen Masroor, Chhavi Dudeja, Sanya Kaushik, Khushi yagi International Journal of Virus Studies-STM Journals Issn: 3049-1924 Date: 2026-05-21 11:41 Volume: 03 Issue: 01 Keyword: Monkeypox virus, Loop-mediated Isothermal Amplification (LAMP), CRISPR, Tecovirimat , recombinant DNA technology, assay optimization Full Text PDF
Views: 6
Submit Manuscript Journals

Abstract

Monkeypox, a zoonotic viral infection caused by the Monkeypox virus of the Orthopoxvirus genus, has recurred as a worldwide public health concern after recent outbreaks outside of its classical endemic areas in Central and West Africa. The resurgence has demanded a thorough reassessment of its epidemiology, mode of transmission, and clinical presentation. In light of these challenges, recombinant DNA technology (rDNA) has emerged as a candidate for developing vaccines, diagnostics, and therapeutic agents, as shown in the successful control of other viral diseases like hepatitis B and HPV. The combination of rDNA and CRISPR-based methods presents a revolutionary strategy for monkeypox surveillance and control. CRISPR-Cas systems—particularly Cas12a and Cas13a—have been shown to be effective for sensing MPXV with high sensitivity and specificity through fluorescence, lateral flow, and smartphone-based readouts. Challenges still exist in crRNA design, assay optimization, and standardization. Furthermore, Loop-mediated Isothermal Amplification (LAMP) directed against A27L and F3L genes of MPXV has shown encouraging sensitivity and specificity and was superior to traditional PCR approaches in some contexts. These diagnostic gains are matched by continued clinical trials for both conventional and emerging vaccine platforms—including MVA-BN, JYNNEOS, and RNA-based constructs such as BNT166a—and antiviral drugs like Tecovirimat. All the same, rapid diagnosis and availability of therapeutics remain significant challenges to monkeypox management. This review brings out the important contribution of new biotechnological tools, specifically rDNA, CRISPR, and LAMP, in revolutionizing existing diagnostic and treatment methods, hence leading to efficient disease management and future outbreak readiness.

Keyword: Monkeypox virus, Loop-mediated Isothermal Amplification (LAMP), CRISPR, Tecovirimat , recombinant DNA technology, assay optimization

Refrences:

  1. Nozaki M. Combined use of bucolome and pyrazolone derivatives (II). Complex formation due to interaction between bucolome and pyrazolones. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 1975 Sep 1;71(6):631-9.
  2. Jamil H, Tariq W, Tahir MJ, Mahfooz RS, Asghar MS, Ahmed A. Human monkeypox expansion from the endemic to non-endemic regions: Control measures. Annals of medicine and surgery. 2022 Jul 1;79.
  3. Gill K, Negi S, Rana N, Kumar P. RDT and genetic engineering: Basic of RDT method, PCR, and application. InBasic Biotechniques for Bioprocess and Bioentrepreneurship 2023 Jan 1 (pp. 207-216). Academic Press.
  4. Gill K, Negi S, Rana N, Kumar P. RDT and genetic engineering: Basic of RDT method, PCR, and application. InBasic Biotechniques for Bioprocess and Bioentrepreneurship 2023 Jan 1 (pp. 207-216). Academic Press.
  5. Nyame J, Punniyakotti S, Khera K, Pal RS, Varadarajan N, Sharma P. Challenges in the treatment and prevention of monkeypox infection; A comprehensive review. Acta Tropica. 2023 Sep 1;245:106960.
  6. Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, Djingarey MH, Olson V, Damon IK, Khalakdina A. Emergence of monkeypox—west and central Africa, 1970–2017. MMWR. Morbidity and mortality weekly report. 2018;67.
  7. Mande G, Akonda I, De Weggheleire A, Brosius I, Liesenborghs L, Bottieau E, Ross N, Gembu GC, Colebunders R, Verheyen E, Ngonda D. Enhanced surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the limitations of symptom-based case definitions. International Journal of Infectious Diseases. 2022 Sep 1;122:647-55.
  8. Elsayed S, Bondy L, Hanage WP. Monkeypox virus infections in humans. Clinical microbiology reviews. 2022 Dec 21;35(4):e00092-22.
  9. Nakazawa Y, Emerson GL, Carroll DS, Zhao H, Li Y, Reynolds MG, Karem KL, Olson VA, Lash RR, Davidson WB, Smith SK. Phylogenetic and ecologic perspectives of a monkeypox outbreak, southern Sudan, 2005. Emerging infectious diseases. 2013 Feb;19(2):237.
  10. Guarner J, Johnson BJ, Paddock CD, Shieh WJ, Goldsmith CS, Reynolds MG, Damon IK, Regnery RL, Zaki SR, Veterinary Monkeypox Virus Working Group. Monkeypox transmission and pathogenesis in prairie dogs. Emerging infectious diseases. 2004 Mar;10(3):426.
  11. Ogoina D, Damon I, Nakoune E. Clinical review of human mpox. Clinical Microbiology and Infection. 2023 Dec 1;29(12):1493-501.
  12. Galassi FM, Sineo L, Papa V, Varotto E. Monkeypox between dermatology and anthropology: a model for evolutionary medicine. Clinics in Dermatology. 2023 May 1;41(3):423-4.
  13. Saied AA. Is monkeypox virus older than we think?. Transboundary and Emerging Diseases. 2022 Sep;69(5):2407-8.
  14. Happi C, Adetifa I, Mbala P, Njouom R, Nakoune E, Happi A, Ndodo N, Ayansola O, Mboowa G, Bedford T, Neher RA. Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus. PLoS Biology. 2022 Aug 23;20(8):e3001769.
  15. McInnes CJ, Damon IK, Smith GL, McFadden G, Isaacs SN, Roper RL, Evans DH, Damaso CR, Carulei O, Wise LM, Lefkowitz EJ. ICTV virus taxonomy profile: Poxviridae 2023. Journal of general virology. 2023 May 17;104(5):001849.
  16. Bryer J, Freeman EE, Rosenbach M. Monkeypox emerges on a global scale: a historical review and dermatologic primer. Journal of the American Academy of Dermatology. 2022 Nov 1;87(5):1069-74.
  17. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS neglected tropical diseases. 2022 Feb 11;16(2):e0010141.
  18. Marennikova SS, Šeluhina EM, Mal’Ceva NN, Ladnyj ID. Poxviruses isolated from clinically ill and asymptomatically infected monkeys and a chimpanzee. Bulletin of the World Health Organization. 1972;46(5):613.
  19. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, Swain GR. The detection of monkeypox in humans in the Western Hemisphere. New England Journal of Medicine. 2004 Jan 22;350(4):342-50.
  20. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. The Lancet infectious diseases. 2004 Jan 1;4(1):15-25.
  21. Parker S, Nuara A, Buller RM, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future microbiology. 2007 Feb 1;2(1):17-34.
  22. Sklenovská N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Frontiers in public health. 2018 Sep 4;6:383729.
  23. Shuvo PA, Roy A, Dhawan M, Chopra H, Emran TB. Recent outbreak of monkeypox: Overview of signs, symptoms, preventive measures, and guideline for supportive management. International Journal of Surgery. 2022 Sep 1;105:106877.
  24. Leon-Figueroa DA, Katterine Bonilla-Aldana D, Pachar M, Romani L, Saldana-Cumpa HM, Anchay-Zuloeta C, Diaz-Torres M, Franco-Paredes C, Antonio Suarez J, David Ramirez J, Paniz-Mondolfi A. Travel medicine and infectious disease. TRAVEL MEDICINE AND INFECTIOUS DISEASE. 2022 Sep 1;49.
  25. Vaughan A, Aarons E, Astbury J, Brooks T, Chand M, Flegg P, Hardman A, Harper N, Jarvis R, Mawdsley S, McGivern M. Human-to-human transmission of monkeypox virus, United Kingdom, October 2018. Emerging infectious diseases. 2020 Apr;26(4):782.
  26. Vaughan A, Aarons E, Astbury J, Brooks T, Chand M, Flegg P, Hardman A, Harper N, Jarvis R, Mawdsley S, McGivern M. Human-to-human transmission of monkeypox virus, United Kingdom, October 2018. Emerging infectious diseases. 2020 Apr;26(4):782.
  27. Ho MW, Traavik T, Olsvik O, Tappeser B, Howard CV, von Weizsacker C, McGavin GC. Gene technology and gene ecology of infectious diseases. Microbial Ecology in Health and Disease. 1998 Jan 1;10(1):33-59.
  28. Snaith RD. Recombinant DNA techniques: An introduction: By RL Rodriguez and RC Tait. Pp 236. addison‐wesley, reading, Mass. 1983.£ 16.95. ISBN 0–201–10870–4.
  29. Di Felice F, Micheli G, Camilloni G. Restriction enzymes and their use in molecular biology: An overview: F Di Felice, G Micheli and G Camilloni. Journal of biosciences. 2019 Jun;44(2):38.
  30. Tabor S. DNA ligases. Current protocols in molecular biology. 1989 Oct;8(1):3-14.
  31. Metanat Y, Viktor P, Amajd A, Kaur I, Hamed AM, Al-Abadi NK, Alwan NH, Chaitanya MV, Lakshmaiya N, Ghildiyal P, Khalaf OM. The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods. Life Sciences. 2024 Jul 1;348:122683.
  32. Chance RE, Frank BH. Research, development, production, and safety of biosynthetic human insulin. Diabetes care. 1993 Dec 1;16(Supplement_3):133-42.
  33. Johnston C, Martin B, Fichant G, Polard P, Claverys JP. Bacterial transformation: distribution, shared mechanisms and divergent control. Nature Reviews Microbiology. 2014 Mar;12(3):181-96.
  34. McGee DJ, Coker C, Harro JM, Mobley HL. Bacterial genetic exchange. Encycl. Life Sci. 2001 May 30.
  35. Ghosh SK, Chatterjee T. Clustered regularly interspaced short palindromic repeats (CRISPR)-associated proteins (Cas)[CRISPR–Cas]: an emerging technique in plant disease detection and management. InGene editing in plants: CRISPR-Cas and its applications 2024 Mar 19 (pp. 589-645). Singapore: Springer Nature Singapore.
  36. Dronina J, Samukaite-Bubniene U, Ramanavicius A. Towards application of CRISPR-Cas12a in the design of modern viral DNA detection tools. Journal of nanobiotechnology. 2022 Jan 21;20(1):41.
  37. Xie S, Qin C, Zhao F, Shang Z, Wang P, Sohail M, Zhang X, Li B. A DNA–Cu nanocluster and exonuclease I integrated label-free reporting system for CRISPR/Cas12a-based SARS-CoV-2 detection with minimized background signals. Journal of Materials Chemistry B. 2022;10(32):6107-17.
  38. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. science. 2012 Aug 17;337(6096):816-21.
  39. Dai Y, Wu Y, Liu G, Gooding JJ. CRISPR mediated biosensing toward understanding cellular biology and point‐of‐care diagnosis. Angewandte Chemie International Edition. 2020 Nov 16;59(47):20754-66.
  40. Chen M, Shafer-Peltier K, Randtke SJ, Peltier E. Competitive association of cations with poly (sodium 4-styrenesulfonate)(PSS) and heavy metal removal from water by PSS-assisted ultrafiltration. Chemical Engineering Journal. 2018 Jul 15;344:155-64.
  41. Zhang B. Genome-Wide Survey and Comparative Analysis of Long Terminal Repeat (LTR) Retrotransposon Families in Four Gossypium Species.
  42. Wang L, Xu C, Zhang S, Chen S, Wang H, Duan Z, Al-Hartomy OA, Wageh S, Wen X, Liu Y, Lin Y. Rapid and ultrasensitive detection of mpox virus using CRISPR/Cas12b-empowered graphene field-effect transistors. Applied Physics Reviews. 2023 Sep 1;10(3).
  43. Singh M, Bindal G, Misra CS, Rath D. The era of Cas12 and Cas13 CRISPR-based disease diagnosis. Critical Reviews in Microbiology. 2022 Nov 2;48(6):714-29.
  44. Hueso L, Martorell S, Sena-Torralba A, Ferrando M, Ferri M, Maquieira A, Ntoumi F, Morais S. Recombinase polymerase amplification technology for point-of-care diagnosis of neglected tropical diseases. International Journal of Infectious Diseases. 2025 Apr 1;153:107831.
  45. Chen Y, Zhao R, Hu X, Wang X. The current status and future prospects of CRISPR-based detection of monkeypox virus: A review. Analytica Chimica Acta. 2025 Jan 22;1336:343295.
  46. Chen H, Cheng X, Wang Y, Han N, Liu L, Wei H, Tu Z, Gu Z, Song R, Wang S, Rong Z. Two-Dimensional Nanozyme-Catalyzed Colorimetric CRISPR Assay for the Microfluidic Detection of Monkeypox Virus. Analytical Chemistry. 2025 Feb 18;97(8):4407-15.
  47. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018 Apr 27;360(6387):439-44.
  48. Patchsung M, Jantarug K, Pattama A, Aphicho K, Suraritdechachai S, Meesawat P, Sappakhaw K, Leelahakorn N, Ruenkam T, Wongsatit T, Athipanyasilp N. Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. Nature biomedical engineering. 2020 Dec;4(12):1140-9.
  49. Tomita N, Mori Y, Kanda H, Notomi T. Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products. Nature protocols. 2008 May;3(5):877-82.
  50. Li Y, Tan G, Lan P, Zhang A, Liu Y, Li R, Li F. Detection of tobamoviruses by RT-PCR using a novel pair of degenerate primers. Journal of Virological Methods. 2018 Sep 1;259:122-8.
  51. Zhou Y, Chen Z. Mpox: a review of laboratory detection techniques: Y. Zhou, Z. Chen. Archives of virology. 2023 Aug;168(8):221.
  52. Feng J, Xue G, Cui X, Du B, Feng Y, Cui J, Zhao H, Gan L, Fan Z, Fu T, Xu Z. Development of a loop-mediated isothermal amplification method for rapid and visual detection of monkeypox virus. Microbiology spectrum. 2022 Oct 26;10(5):e02714-22.
  53. Hussein MH, Mohamad MA, Dhakal S, Sharma M, Mohamad M. Cellulitis or Lymphadenopathy: A challenging monkeypox virus infection case. Cureus. 2023 Jun 5;15(6).
  54. Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J. Clinical features and management of human monkeypox: a retrospective observational study in the UK. The Lancet Infectious Diseases. 2022 Aug 1;22(8):1153-62.
  55. Berthet N, Descorps-Declère S, Besombes C, Curaudeau M, Nkili Meyong AA, Selekon B, Labouba I, Gonofio EC, Ouilibona RS, Simo Tchetgna HD, Feher M. Genomic history of human monkey pox infections in the Central African Republic between 2001 and 2018. Scientific reports. 2021 Jun 22;11(1):13085.
  56. Ladnyj ID, Ziegler P, Kima EJ. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bulletin of the World Health Organization. 1972;46(5):593.
  57. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, Apea V. Monkeypox virus infection in humans across 16 countries—April–June 2022. New England Journal of Medicine. 2022 Aug 25;387(8):679-91.
  58. Sun W. Monkeypox, smallpox, FDA, and accelerated approval of vaccines–A regulatory perspective. Vaccine. 2023 May 15;41(25):3681.
  59. Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, Mamadu I, Akinpelu A, Ahmad A, Burga J, Ndoreraho A. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. The Lancet Infectious Diseases. 2019 Aug 1;19(8):872-9.
  60. Schnierle BS. Monkeypox goes north: ongoing worldwide monkeypox infections in humans. Viruses. 2022 Aug 25;14(9):1874.
  61. Rahman MT, Sobur MA, Islam MS, Ievy S, Hossain MJ, El Zowalaty ME, Rahman AT, Ashour HM. Zoonotic diseases: etiology, impact, and control. Microorganisms. 2020 Sep 12;8(9):1405.
  62. Louten J. Virus transmission and epidemiology. Essential human virology. 2016 May 6:71.
  63. Mims CA. The origin of major human infections and the crucial role of person-to-person spread. Epidemiology & Infection. 1991 Jun;106(3):423-33.
  64. Heskin J, Belfield A, Milne C, Brown N, Walters Y, Scott C, Bracchi M, Moore LS, Mughal N, Rampling T, Winston A. Transmission of monkeypox virus through sexual contact–A novel route of infection. The Journal of infection. 2022 Jun 1;85(3):334.
  65. Ligon BL. Monkeypox: a review of the history and emergence in the Western hemisphere. InSeminars in pediatric infectious diseases 2004 Oct 1 (Vol. 15, No. 4, pp. 280-287). WB Saunders.
  66. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS neglected tropical diseases. 2019 Oct 16;13(10):e0007791.
  67. Brisse ME, Hickman HD. Viral Infection and Dissemination Through the Lymphatic System. Microorganisms. 2025 Feb 18;13(2):443.
  68. Islam MA, Mumin J, Haque MM, Haque MA, Khan A, Bhattacharya P, Haque MA. Monkeypox virus (MPXV): A Brief account of global spread, epidemiology, virology, clinical features, pathogenesis, and therapeutic interventions. Infectious medicine. 2023 Dec 1;2(4):262-72.
  69. Araf Y, Nipa JF, Naher S, Maliha ST, Rahman H, Arafat KI, Munif MR, Uddin MJ, Jeba N, Saha S, Zhai J. Insights into the transmission, host range, genomics, vaccination, and current epidemiology of the monkeypox virus. Veterinary Medicine International. 2024;2024(1):8839830.
  70. Kadiyala KG, Goutham K, Katari NK, Vanipenta Y. Vaccines, Diagnosis, and Treatment of Infectious Diseases. Sustainable Nanomaterials for Treatment and Diagnosis of Infectious Diseases. 2025 Feb 26:113-38.
  71. Altindis M, Puca E, Shapo L. Diagnosis of monkeypox virus–An overview. Travel medicine and infectious disease. 2022 Nov 1;50:102459.
  72. da Silva SJ, Kohl A, Pena L, Pardee K. Clinical and laboratory diagnosis of monkeypox (mpox): Current status and future directions. IScience. 2023 Jun 16;26(6).
  73. Johri N, Kumar D, Nagar P, Maurya A, Vengat M, Jain P. Clinical manifestations of human monkeypox infection and implications for outbreak strategy. Health Sciences Review. 2022 Dec 1;5:100055.
  74. Yi XM, Lei YL, Li M, Zhong L, Li S. The monkeypox virus-host interplays. Cell insight. 2024 Oct 1;3(5):100185.
  75. Wang R, Lan C, Benlagha K, Camara NO, Miller H, Kubo M, Heegaard S, Lee P, Yang L, Forsman H, Li X. The interaction of innate immune and adaptive immune system. MedComm. 2024 Oct;5(10):e714.
  76. Azari PP, Rukerd MR, Charostad J, Bashash D, Farsiu N, Behzadi S, Khoshnazar SM, Heydari S, Nakhaie M. Monkeypox (Mpox) vs. Innate immune responses: Insights into evasion mechanisms and potential therapeutic strategies. Cytokine. 2024 Nov 1;183:156751.
  77. Banjar WM, Alaqeel MK. Monkeypox stigma and risk communication; understanding the dilemma. Journal of infection and public health. 2024 Apr 1;17:4-7.
  78. Dahmana H, Granjon L, Diagne C, Davoust B, Fenollar F, Mediannikov O. Rodents as hosts of pathogens and related zoonotic disease risk. Pathogens. 2020 Mar 10;9(3):202.
  79. Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, Zumla A. Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infectious disease clinics of North America. 2019 Apr 11;33(4):1027.
  80. Grant R, Nguyen LB, Breban R. Modelling human-to-human transmission of monkeypox. Bulletin of the World Health Organization. 2020 Jul 8;98(9):638.
  81. Ahmed SK, El-Kader RG, Abdulqadir SO, Abdullah AJ, El-Shall NA, Chandran D, Dey A, Emran TB, Dhama K. Monkeypox clinical symptoms, pathology, and advances in management and treatment options: an update. International Journal of Surgery. 2023 Sep 1;109(9):2837-40.
  82. Kang JH. Febrile illness with skin rashes. Infection & chemotherapy. 2015 Sep 30;47(3):155.
  83. Griffiths EC, Pedersen AB, Fenton A, Petchey OL. The nature and consequences of coinfection in humans. Journal of Infection. 2011 Sep 1;63(3):200-6.
  84. Gurnani B, Kaur K, Chaudhary S, Balakrishnan H. Ophthalmic manifestations of monkeypox infection. Indian Journal of Ophthalmology. 2023 May 1;71(5):1687-97.
  85. Gupta AK, Talukder M, Rosen T, Piguet V. Differential diagnosis, prevention, and treatment of mpox (monkeypox): a review for dermatologists. American Journal of Clinical Dermatology. 2023 Jul;24(4):541-56.
  86. Patel A, Bilinska J, Tam JC, Fontoura DD, Mason CY, Daunt A, Snell LB, Murphy J, Potter J, Tuudah C, Sundramoorthi R. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. bmj. 2022 Jul 28;378.
  87. Hwang KA, Ahn JH, Nam JH. Diagnosis of viral infection using real-time polymerase chain reaction. Journal of Bacteriology and Virology. 2018 Mar;48(1):1-3.
  88. Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SG, Strelow LI, Wong SW, Yoshihara P, Hanifin JM, Slifka MK. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nature medicine. 2005 Sep 1;11(9):1005-11.
  89. Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, Hettiarachchi D, Mathangasinghe Y, Weeratunga P, Wickramasinghe D, Bergman H. Antibody tests for identification of current and past infection with SARS‐CoV‐2. Cochrane database of Systematic reviews. 2022(11).
  90. Burrell CJ, Howard CR, Murphy FA. Laboratory diagnosis of virus diseases. Fenner and White’s medical virology. 2016 Nov 11:135.
  91. Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, Orkin CM. Monkeypox. The Lancet. 2023 Jan 7;401(10370):60-74.
  92. Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP. A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of modified vaccinia Ankara smallpox vaccine (MVA-BN®) in 56-80-year-old subjects. PloS one. 2016 Jun 21;11(6):e0157335.
  93. Cochrane Infectious Diseases Group, Fox T, Gould S, Princy N, Rowland T, Lutje V, Kuehn R. Therapeutics for treating mpox in humans. Cochrane Database of Systematic Reviews. 1996 Sep 1;2023(3).
  94. Mazurkov OY, Kabanov AS, Shishkina LN, Sergeev AA, Skarnovich MO, Bormotov NI, Skarnovich MA, Ovchinnikova AS, Titova KA, Galahova DO, Bulychev LE. New effective chemically synthesized anti-smallpox compound NIOCH-14. Journal of General Virology. 2016 May 1;97(5):1229-39.
  95. Grabenstein JD, Hacker A. Vaccines against mpox: MVA-BN and LC16m8. Expert Review of Vaccines. 2024 Dec 31;23(1):796-811.
  96. Grabenstein JD, Hacker A. Vaccines against mpox: MVA-BN and LC16m8. Expert Review of Vaccines. 2024 Dec 31;23(1):796-811.
  97. Mucker EM, Freyn AW, Bixler SL, Cizmeci D, Atyeo C, Earl PL, Natarajan H, Santos G, Frey TR, Levin RH, Meni A. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell. 2024 Oct 3;187(20):5540-53.
  98. Russo D, Garcia-Gutierrez JV, Soverini S, Baccarani M. Chronic myeloid leukemia prognosis and therapy: criticisms and perspectives. Journal of clinical medicine. 2020 Jun 2;9(6):1709.
  99. de la Calle-Prieto F, Muñoz ME, Ramírez G, Díaz-Menéndez M, Velasco M, Galparsoro HA, Lletí MS, Forte TM, Blanco JL, Mora-Rillo M, Arsuaga M. Treatment and prevention of monkeypox. Enfermedades infecciosas y microbiologia clinica (English ed.). 2023 Dec 1;41(10):629-34.
  100. Yong SE, Ng OT, Ho ZJ, Mak TM, Marimuthu K, Vasoo S, Yeo TW, Ng YK, Cui L, Ferdous Z, Chia PY. Imported monkeypox, singapore. Emerging infectious diseases. 2020 Aug;26(8):1826.
  101. Imran M, Alshammari MK, Arora MK, Dubey AK, Das SS, Kamal M, Alqahtani AS, Sahloly MA, Alshammari AH, Alhomam HM, Mahzari AM. Oral brincidofovir therapy for monkeypox outbreak: a focused review on the therapeutic potential, clinical studies, patent literature, and prospects. Biomedicines. 2023 Jan 19;11(2):278.
  102. Philippidis A. StockWatch: Novavax Hits 52-Week Low as Rivals Win FDA Omicron Booster OKs: Jounce falls on clinical setback; Liquidia rises on patent rulings; Chimerix soars on BARDA contract; Smaller IPO scores for Shuttle Pharma. GEN Edge. 2022 Sep 1;4(1):genedge-4.
  103. De Clercq E, Jiang Y, Li G. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf. Travel Medicine and Infectious Disease. 2023 Mar 1;52:102528.
  104. Quarleri J, Delpino MV, Galvan V. Monkeypox: considerations for the understanding and containment of the current outbreak in non-endemic countries. Geroscience. 2022 Aug;44(4):2095-103.
  105. Comerford I, McColl SR. Atypical chemokine receptors in the immune system. Nature Reviews Immunology. 2024 Oct;24(10):753-69.
  106. Siendones E, SantaCruz-Calvo S, Martín-Montalvo A, Cascajo MV, Ariza J, López-Lluch G, Villalba JM, Acquaviva-Bourdain C, Roze E, Bernier M, de Cabo R. Membrane-bound CYB5R3 is a common effector of nutritional and oxidative stress response through FOXO3a and Nrf2. Antioxidants & redox signaling. 2014 Oct;21(12):1708-25.
  107. Adamo S, Gao Y, Sekine T, Mily A, Wu J, Storgärd E, Westergren V, Filen F, Treutiger CJ, Sandberg JK, Sällberg M. Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. Cell host & microbe. 2023 Jun 14;31(6):928-36.
  108. Xu T, Chen Z, Zhou X, Wang L, Zhou F, Yao D, Zhou B, Becker B. The central renin–angiotensin system: A genetic pathway, functional decoding, and selective target engagement characterization in humans. Proceedings of the National Academy of Sciences. 2024 Feb 20;121(8):e2306936121.
  109. International MHC and Autoimmunity Genetics Network (IMAGEN)*, Rioux JD, Goyette P, Vyse TJ, Hammarström L, Fernando MM, Green T, De Jager PL, Foisy S, Wang J, de Bakker PI. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proceedings of the National Academy of Sciences. 2009 Nov 3;106(44):18680-5.
  110. Chakravarty N, Hemani D, Paravastu R, Ahmad Z, Palani SN, Arumugaswami V, Kumar A. Mpox Virus and its ocular surface manifestations. The ocular surface. 2024 Oct 1;34:108-21.
  111. Parnian R, Heydarifard F, Mousavi FS, Heydarifard Z, Zandi M. Innate immune response to monkeypox virus infection: mechanisms and immune escape. Journal of innate immunity. 2024 May 27;16(1):413-24.
  112. Schmidt N, Domingues P, Golebiowski F, Patzina C, Tatham MH, Hay RT, Hale BG. An influenza virus-triggered SUMO switch orchestrates co-opted endogenous retroviruses to stimulate host antiviral immunity. Proceedings of the National Academy of Sciences. 2019 Aug 27;116(35):17399-408.
>